Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

Overview of attention for article published in Breast Cancer Research, November 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (81st percentile)
Good Attention Score compared to outputs of the same age and source (67th percentile)

Mentioned by

news: 1 news outlet

twitter: 4 X users

Citations

dimensions_citation: 21 Dimensions

Readers on

mendeley: 60 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 1 news story.

Early data signal immunopriming effect of bevacizumab in advanced breast cancer

medwireNews, 21 Dec 2020

medwireNews: Combined treatment with durvalumab plus bevacizumab could benefit women with HER2-negative advanced breast cancer…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.